Aug 17
BSPK · Bespoke Extracts, Inc.
$0.00
At close · Nov 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had negative cash flows from operations of $123,562 for period ended September 30, 2025, and a working capital deficit of $1,675,749 and accumulated deficit of $26,947,831, as of September 30, 2025. This raises substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of these financial statements.”View the 10-Q filed Nov 12, 2025
Market Cap
$6,752
Shares
11.25M
Volume · Nov 9
134
Avg daily vol (8 sessions)
1209
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.28
Avg vol 30d5K
Short int8K · 0.1% of shares · 22.7d
Short vol18%
DataJan 2020–Nov 2026
Filing10-Q · Nov 12
Latest documents
2026
Jul 6
Current report
8-K
Events of Jun 30
Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity
AI summary on its way
May 18
Mar 31
2025
Nov 19
Current report
8-K
Events of Nov 12
Financial results
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.42M
Trailing 12 months
Net income (TTM)
−$730,564
Trailing 12 months
Revenue growth YoY
+68.6%
Year over year
Operating margin
-45.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.97M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.8%
Year over year · more shares
Price change (1Y)
-99.5%
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−100%
below
Price vs 50-day avg
−100%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−100%
trailing
6-month return
−99%
trailing
YTD return
−100%
this year
Relative strength
−102%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.07% of shares out · ▲ +1.0% MoM · 22.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+42%
Y/Y
Gross margin
41%
contracting
EPS growth
+33%
Y/Y
Free cash flow
$-889.8K
Quant / Vol
risk profile
Volatility
485%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
3216.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−100%
Bearish
Price vs 50-day avg
−100%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.07% of shares out · ▲ +1.0% MoM · 22.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -100%
vs 50-day avg -100%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BSPK
this stock
Bespoke Extracts, Inc.
|
$6,752 | -99.7% | +42.3% | — | 0.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.48B | +35.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$54.01B | +11.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$50.93B | +39.9% | +4.3% | 99.2 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BSPK | -62.5% | -99.6% | -99.1% | +20.0% | -99.7% |
| SPY | +0.1% | -3.3% | +2.6% | -0.4% | +10.4% |
| vs SPY | -62.6% | -96.3% | -101.6% | +20.4% | -110.1% |